Blood glucose monitoring

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on: 
Lundi, février 12, 2024
Software, Mobile, Wireless, Professional Services, Consumer Electronics, Apps, Applications, Medical Devices, Technology, Health Technology, Health Insurance, Insurance, Health, Diabetes, Blood glucose monitoring, MAC, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Lundi, février 12, 2024
Blood glucose monitoring, MAC, Diabetes, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Ascensia Diabetes Care takes part in MedTech Europe's 'Connecting the Dots' Film Series, with a film on Eversense® CGM

Retrieved on: 
Mardi, décembre 5, 2023
Safety, Practitioner, Dots, Commercial Operating System, Physician, BBC Studios, Collection, CGM, Patient, Blood glucose monitoring, TSE, BBC, Diabetes, BGM, Medical device, MedTech Europe

Parsippany, N.J.  , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita. Presented by MedTech Europe and including a film produced for the organization by BBC StoryWorks Commercial Productions, the branded content studio of BBC Studios, the 'Connecting the Dots' series brings into focus the evolution of medical technologies, celebrating both cutting-edge innovations and enduring healthcare solutions that empower people. The series is available on www.medtechconnectingthedots.com.

Key Points: 
  • Parsippany, N.J. , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita.
  • In particular, the film highlights the transformation that Eversense, the only long-term CGM system, can deliver to people with diabetes, through the lens of Troy and his endocrinologist Dr. Rakesh Patel.
  • In the film, Troy said, "I'm constantly on the road driving for my job, so managing my diabetes has become a juggling act.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

ASCENSIA DIABETES CARE POLAND EARNS GREAT PLACE TO WORK CERTIFICATION

Retrieved on: 
Jeudi, octobre 19, 2023
CGM, BGM, Blood glucose monitoring, Great Places, TSE, Management

WARSAW, Poland, Oct. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that Ascensia Diabetes Care Poland has been awarded Great Place To Work certification.

Key Points: 
  • WARSAW, Poland, Oct. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that Ascensia Diabetes Care Poland has been awarded Great Place To Work certification.
  • The prestigious certification is awarded based on employee feedback about their experience working at Ascensia Diabetes Care Poland.
  • "For more than 80 years, the Ascensia team has innovated glucose monitoring technology and systems, showing consistent commitment to the global diabetes community as we built a positive workplace culture rooted in helping others," said Pawel Lupinski, Head of Ascensia Diabetes Care Poland.
  • "This award is a positive reflection of the great place to work that the team has built at Ascensia Diabetes Care Poland and we hope it encourages people to come and innovate at Ascensia as we continue to grow and thrive."

ASCENSIA ANNOUNCES ART AND PHOTO COMPETITION FOR WORLD DIABETES DAY 2023

Retrieved on: 
Mardi, septembre 19, 2023
CGM, Diabetes, Paint, TSE, System, World Diabetes Day, IDF, Blood glucose monitoring, BGM, International Diabetes Federation, Creativity, Collection, Disease, Pharmaceutical industry

PARSIPPANY, N.J., Sept. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, owner of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has opened submissions for its successful art and photo competition in support of World Diabetes Day 2023. This year, Ascensia's global competition is themed around diabetes in real life, aiming to capture the genuine challenges, successes and day-to-day realities of people living with diabetes. 

Key Points: 
  • PARSIPPANY, N.J., Sept. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, owner of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has opened submissions for its successful art and photo competition in support of World Diabetes Day 2023.
  • This year, Ascensia's global competition is themed around diabetes in real life, aiming to capture the genuine challenges, successes and day-to-day realities of people living with diabetes.
  • Ascensia's 'This is Diabetes, This is Real' competition seeks to gather a collection of original artworks submitted by people across the world, with each one telling a personal story about their journey with diabetes.
  • Rob Schumm, CEO of Ascensia Diabetes Care, commented: "World Diabetes Day is an important day to us at Ascensia and we are proud to support IDF on this initiative for the eighth consecutive year.

ASCENSIA ANNOUNCES ART AND PHOTO COMPETITION FOR WORLD DIABETES DAY 2023

Retrieved on: 
Mardi, septembre 19, 2023
CGM, Diabetes, Paint, TSE, System, World Diabetes Day, IDF, Blood glucose monitoring, BGM, International Diabetes Federation, Creativity, Collection, Disease, Pharmaceutical industry

PARSIPPANY, N.J., Sept. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, owner of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has opened submissions for its successful art and photo competition in support of World Diabetes Day 2023. This year, Ascensia's global competition is themed around diabetes in real life, aiming to capture the genuine challenges, successes and day-to-day realities of people living with diabetes. 

Key Points: 
  • PARSIPPANY, N.J., Sept. 19, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, owner of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has opened submissions for its successful art and photo competition in support of World Diabetes Day 2023.
  • This year, Ascensia's global competition is themed around diabetes in real life, aiming to capture the genuine challenges, successes and day-to-day realities of people living with diabetes.
  • Ascensia's 'This is Diabetes, This is Real' competition seeks to gather a collection of original artworks submitted by people across the world, with each one telling a personal story about their journey with diabetes.
  • Rob Schumm, CEO of Ascensia Diabetes Care, commented: "World Diabetes Day is an important day to us at Ascensia and we are proud to support IDF on this initiative for the eighth consecutive year.

$33.88 Bn Glucose Monitoring Market - Global Forecast to 2029 - Increasing Demand for Minimally or Non-Invasive and Point-Of-Care Devices Bodes well for the Sector - ResearchAndMarkets.com

Retrieved on: 
Jeudi, juin 8, 2023
Diabetes, Health, Medical Devices, CGM, Self, Prevalence, Urine, Lancet, Blood glucose monitoring, Ageing, Diffusion, Privacy, Row, Hospital, Patient, Investment, Blood, OTC, Medical device, Video game, Invasive

Glucose monitoring global market is expected to grow at a double digit CAGR from 2022 to 2029 reach $33,886.4 million by 2029.

Key Points: 
  • Glucose monitoring global market is expected to grow at a double digit CAGR from 2022 to 2029 reach $33,886.4 million by 2029.
  • The products market is divided into three segments, namely, Invasive, non-Invasive and lab-based glucose monitoring products.
  • The non-invasive glucose monitoring segment is projected to grow at mid single digit CAGR from 2022 to 2029.
  • The Self glucose monitoring products are further sub-segmented into blood glucose monitors, blood glucose test strips, and lancets & others.

ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Mardi, mai 9, 2023
CGM, Insurance, Diabetes, SENS, TSE, Safety, Physician, Blood glucose monitoring, BGM, MARD, Patient, Practitioner, Contour, NYSE, Medical device

PARSIPPANY, N.J., May 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.

Key Points: 
  • PARSIPPANY, N.J., May 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.
  • Created by Ascensia, the Eversense PASS program has been helping eligible patients in the U.S. access Eversense E3 and its benefits since April 2022.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK

Retrieved on: 
Lundi, avril 24, 2023
CGM, Partnership, SENS, Marketing, TSE, Safety, Type 2 diabetes, Blood glucose monitoring, BGM, Research, Medicare, Patient, DOI, Longevity, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Medical device, Pharmaceutical industry, Nursing

"The last year has really seen our partnership with Senseonics go from strength to strength," said Rob Schumm, President and CEO of Ascensia Diabetes Care.

Key Points: 
  • "The last year has really seen our partnership with Senseonics go from strength to strength," said Rob Schumm, President and CEO of Ascensia Diabetes Care.
  • Meanwhile, Senseonics has been focused on delivering innovation based on the feedback that we both hear from patients.
  • In April 2022, Ascensia launched the Eversense® E3 CGM System for patients in the U.S., shortly after it was approved by the U.S. Food and Drug Administration (FDA).
  • Eversense CGM Systems and the Eversense CGM App are available across the US and select countries in Europe.

ASCENSIA DIABETES CARE COLLABORATES WITH SNAQ TO SUPPORT MEALTIME DECISION-MAKING FOR PEOPLE WITH DIABETES

Retrieved on: 
Mardi, février 21, 2023
Online, CGM, Marketing, Blood, Meal, Diabetes, Food, PWD, BGM, Blood glucose monitoring, Learning, Medical device

Collaborating to integrate their technologies, Ascensia and SNAQ will empower more PWDs to make impactful mealtime decisions, with a goal to improve diabetes management.

Key Points: 
  • Collaborating to integrate their technologies, Ascensia and SNAQ will empower more PWDs to make impactful mealtime decisions, with a goal to improve diabetes management.
  • Users of Ascensia's world-renowned CONTOUR BGM portfolio will now be able to seamlessly incorporate SNAQ into their diabetes management regimen, in order to make data-driven decisions about food and nutrition.
  • SNAQ meal data can also be shared with GlucoContro.Online , Ascensia's streamlined platform, which enables PWDs to seamlessly access, analyze and share their diabetes data.
  • Working with Ascensia's team is an exciting opportunity for SNAQ to grow and continue making a difference for people living with diabetes."